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Abstract
Mammalian inducible nitric oxide synthase (iNOS) catalyzes the production of L-citrulline and nitric
oxide (NO) from L-arginine and O2. The Soret peak in the spectrum of the iNOS heme domain
(iNOSoxy) shifts from 423 to 390 nm upon addition of a sensitizer-wire, [ReI-imidazole-(CH2)8-
nitroarginine]+, or [ReC8argNO2]+, owing to partial displacement of the water ligand in the active
site. From analysis of competitive binding experiments with imidazole, the dissociation constant
(Kd) for [ReC8argNO2]+:iNOSoxy was determined to be 3.0 ± 0.1 µM, confirming that the sensitizer-
wire binds with higher affinity than both L-arginine (Kd = 22 ± 5 µM) and imidazole (Kd = 14 ± 3
µM). Laser excitation (355 nm) of [ReC8argNO2]+:iNOSoxy triggers electron transfer to the active
site of the enzyme, producing a ferroheme in less than ~1 µs.
INTRODUCTION
Nitric oxide (NO) is an important secondary signaling molecule that has diverse biological
functions, including neurotransmission, blood pressure regulation, and immune response.1–
3 All three isoforms of homodimeric nitric oxide synthase (NOS) (inducible, endothelial, and
neuronal) catalyze the reaction between L-arginine and dioxygen to produce L-citrulline and
NO. The N-terminal oxygenase domain contains binding sites for an iron protoporphyrin IX
(heme), tetrahydrobiopterin (BH4), and L-arginine.4–6 The C-terminal reductase domain, with
binding sites for flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and
nicotinamide adenine dinucleotide phosphate (NADPH), is the source of electrons during the
catalytic cycle.7 At the interface of the two domains is a flexible peptide linker containing the
binding site for calmodulin (CAM).8
We have shown that several sensitizer-linked substrates bind with high affinity to the active-
site channel of the oxygenase domain of inducible NOS (iNOSoxy, with the reductase domain
cleaved at the CAM linker site).9,10 Here we report that a Re(I) sensitizer coupled to nitro-L-
arginine by an imidazole-alkyl molecular wire can be employed to trigger rapid photoreduction
of the ferriheme in the active site of the enzyme. The Re-wire described here has the distinction
that it bears a functional group structurally similar to the native enzyme substrate and supports
rapid electron transfer into the heme active site.
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EXPERIMENTAL SECTION
General
Chemicals were obtained from Aldrich unless stated otherwise. Absorption spectra were
recorded on an Agilent 8453 spectrometer. Steady-state luminescence was recorded using a
Flurolog Model FL3-11 fluorometer equipped with a Hamamatsu R928 PMT. Luminescence
was measured following excitation at 355 nm; the PMT was equipped with a 405 nm long pass
filter to remove scattered excitation light during data collection.
Bromooctylphthalamide (BrC8phth)
Phthalamide (1.0 g, 6.8mmol) was added to a flask containing 1.0 g (7.5 mmol) K2CO3 and
10 mL (0.5 M) DMF. Dibromohexane (Br2C8, 1.4 mL, 7.5 mmol) was added and stirred
overnight (12 h) at room temperature. The reaction mixture was concentrated by rotary
evaporation and purified by flash column chromatography (6:1 Hex:EtAc eluent). 1H NMR
(300 MHz, CDCl3): δ (ppm) 1.2–1.4 (m, 8H), 1.6 (m, 2H), 1.9 (m, 2H), 3.4 (t, 2H), 3.7 (t, 2H),
7.7 (dd, 2H), 7.9 (dd, 2H).
Imidazolyl-octyl-pthalamide
Imidazole (200 mg, 3.2 mmol) was stirred in 5.0 mL (0.60 M) anhydrous DMF. Solid NaH
(78 mg, 3.5 mmol) of was added to the reaction and stirred for 2 h. BrC8phth (1.0 g, 3.2 mmol)
was added and stirred overnight at 40 °C. The reaction mixture was concentrated by rotary
evaporation to remove DMF. Water (50 mL) and toluene (20 mL) were added to the oil in a
separation funnel. The toluene layer was collected and product was further extracted from the
water layer with another 20 mL toluene. This procedure was repeated 3 times. The organic
layer was dried over MgSO4; the MgSO4 was removed by gravity filtration and the organic
layer was concentrated by rotary evaporation, yielding product, a pale yellow solid
(PhthC8imid) (490 mg, 51% yield). 1H NMR (300 MHz, CDCl3): δ (ppm) 1.2–1.4 (m, 8H),
1.6 (m, 2H), 1.8 (m, 2H), 3.6 (t, 2H), 3.9 (t, 2H), 6.9 (s, 1H), 7.0 (s, 1H), 7.1 (s, 1H), 7.7 (dd,
2H), 7.9 (dd, 2H).
Imidazolyl-octyl-amine (1)
PhthC8imid (270 mg, 0.83 mmol) and N2H2 (281 µL, 5.8 mmol) were stirred in 1.0 mL (0.8
M) EtOH for 2 h. A white precipitate formed and was removed by vacuum filtration through
a filter frit. The solid was washed with more EtOH. The filtrate was collected and concentrated
by rotary evaporation. The product (NH2C8imid) was carried onto the next step without further
purification (300 mg, 100% yield). 1H NMR (300 MHz, CDCl3): δ (ppm) 1.2–1.4 (m, 8H), 1.6
(m, 2H), 1.8 (m, 2H), 2.6 (t, 2H), 3.9 (t, 2H), 6.9 (s, 1H), 7.0 (s, 1H), 7.1 (s, 1H).
Imidazolyl-octyl-BOC-nitroarginine
BOC-nitroarginine (1.0 g, 3.1 mmol) and 1 (1.2 g, 6.2 mmol) were stirred with DCC (1.3 g,
6.2 mmol) in anhydrous THF (45 mL) at 50°C. White solid DHU precipitated and was removed
by vacuum filtration through a frit containing celite. The filtrate was concentrated by rotary
evaporation and purified by flash column chromatography (50:3 CH2Cl2:MeOH). The product
was collected as a clear oil (800 mg, 50% yield). 1H NMR (300 MHz, CD3OD): δ (ppm) 1.2–
1.8 (m, 18H); 1.5 (s, 9H); 3.2 (t, 2H); 4.0 (t, 2H); 6.9 (s, 1H); 7.1 (s, 1H); 7.6 (s, 1H). 13C NMR
(300 MHz, CD3OD): δ (ppm) 20–30, 39.9, 40.1, 53, 55, 80, 120, 129, 139, 159, 160, 172.
Imidazole-octyl-nitroarginine (2)
Imidazole-octyl-BOC-nitroarginine (700 mg, 1.4 mmol) was chilled to 0 °C in 15 mL
CH2Cl2. TFA (2.1 mL) was added drop wise. Once the reaction was completed, an aqueous
sodium bicarbonate work up was conducted. The organic layer was collected and concentrated.
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The product was purified by flash column chromatography (90:1 CH2Cl2:MeOH) and collected
as a clear oil (200 mg, 48% yield). 1H NMR (300 MHz, CD3CN): δ (ppm) 1.2–1.8 (m, 18H);
3.1 (t, 2H); 3.9 (t, 2H); 6.9 (s, 1H); 7.1 (s, 1H); 7.5 (s, 1H). 13C NMR (300 MHz, CD3OD): δ
(ppm) 24.5, 26.9, 27.1, 29.0, 29.2, 29.9, 30.5, 31.9, 32.5, 33.5, 39.9, 51.5, 120, 126.5, 128, 131,
134.
[Re(CO)3(4,7-dimethylphenanthroline)(imid-C8-NH-nitroarginine)]BF4, [ReC8argNO2]BF4
Re(CO)3(dmp)(THF) (145 mg, 0.22 mmol) was stirred with 100 mg (0.25 mmol) of 2 in 10
mL 1:1 CH2Cl2:THF at 50 °C for 2 days. The yellow precipitate was removed by vacuum
filtration through a filter frit and the filtrate was collected and concentrated by rotary
evaporation. The product was purified by flash column chromatography (90:1 CH2Cl2:MeOH)
and collected as a yellow solid (100 mg, 45% yield). 1H NMR (300 MHz, CD2Cl2): δ (ppm)
1.0 (broad s, 1H); 1.2–1.8 (m, 18H); 3.0 (s, 6H); 3.2 (t, 2H); 3.4 (br s, 1H); 3.7 (t, 2H); 6.1 (br
s, 1H); 6.4 (s, 1H); 6.7 (s, 1H); 7.3 (s, 1H); 7.9 (d, 2H); 8.3 (d, 2H); 9.4 (d, 2H). 19F NMR (300
MHz, CD2Cl2): δ (ppm) -151.1 (4F). ESI/MS (m/z)+: 880.3 [M]+ (calc 879.3).
Expression and Purification of iNOSoxy
Escherichia coli JM109 competent cells and pCWori plasmid (ampicillin resistance, tac-tac
promoter) were provided by M. Marletta (University of California, Berkeley). iNOSoxy was
overexpressed in E.coli following literature procedures11,12 with the following alterations:
fresh cell pellets from 6 L of culture were resuspended in two rounds of 40 mL B-Per lysis
buffer (Pierce) containing 10 µg/mL benzamidine, 5 µg/mL pefabloc, 1 µg/mL each of
pepstatin, antipain, chymostatin, and chyotrypsin, 100 µg/mL DNAse, 100 µg/mL RNAse, 500
µg/mL lysozyme, and 20 mM imidazole per liter of cells. Cells in lysis buffer solution were
shaken for 1 h at 4 °C. The supernatant was collected after centrifugation and loaded directly
onto a 5 mL His-Trap nickel column (Amersham). The column was washed with 20 column
volumes of 20 mM imidazole in 50 mM sodium phosphate and 300 mM sodium chloride buffer
at pH 8. The protein was then eluted with a linear gradient of imidazole (20 – 150 mM). The
protein-containing fractions were concentrated to 5 mL over an Amicon Ultra filtration device
(10,000 MWCO, Millipore) and loaded onto a Superdex 200 gel filtration column (HiLoad
26/60, Amersham).
Preparation of iNOSoxy Samples
Before every experiment, a 100 µL aliquot of 100 µM 6 iNOSoxy was thawed on ice and filtered
through a PD10 desalting column (BioRad). The PD10 column removed any excess imidazole
bound to the protein during purification. The storing buffer was exchanged for a 50/50 mM
KPi/KCl buffer at pH 7.4 by the same method. The protein concentration in the stock solution
was 20 µM (in 1 mL buffer after the PD10 column). [ReC8argNO2]BF4 was added from a 5
mM stock ethanol solution to protein solution, keeping the ethanol concentration <2% for every
sample (final volume changes were <2% of the initial volume).
Dissociation Constants
Wire affinities were determined by saturation-binding experiments analyzed by three different
methods: double reciprocal plots from steady-state absorption data, Scatchard analysis of
steady-state fluorescence experiments,13,14 and extrapolated free-to-bound substrate ratios
from transient luminescence decay traces. Equilibria from competitive-binding experiments
involving imidazole (Kd = 14 ± 3 µM) and [ReC8argNO2]BF4 were analyzed using a literature
spectral perturbation method.15,16
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Transient Luminescence and Absorption Spectroscopy
All laser experiments were carried out in atmosphere-controlled, 1-cm pathlength cuvettes
equipped with Kontes valves for pump and purge cycles. Transient luminescence and
absorbance decay traces were obtained using a frequency-tripled Nd:YAG laser (λex = 355
nm).17,18 The instrument has a response limit of approximately 10 ns. Transient luminescence
decay were fit using a nonlinear least-squares algorithm according to the function
where n = 1 – 2 for mono- and bi-exponential decays, respectively; kn is the luminescence
decay rate constant for the bound- and free-wire at time t; and cn is the amplitude of bound-
and free-wire. The amplitudes of the decay traces were used to determine the fractions of bound
and free wire (c1/(c1 + c2) = [Re]b/[Re]o); c2/(c1 + c2) = [Re]f/[Re]o). The binding constant for
the iNOSoxy:[ReC8argNO2]+ complex was calculated from the following expression:
where [P]o and [S]o are the initial concentrations of protein and [ReC8argNO2]+., and [S]i,
[S]f, [S]b, are the initial, free, and bound concentrations of [ReC8argNO2]+.
RESULTS AND DISCUSSION
Synthesis of [ReC8argNO2]BF4
The imidazole-wire synthesis required six steps (Scheme 1). Deprotonation of the phthalamide
ligand in the presence of dibromooctane produced bromo-octyl-N-phthalamide. Utilizing a
NaH deprotonation reaction of the imidazole secondary amine, the bromo-octyl-N-
phthalamide was coupled with imidazole to produce phthalyl-octyl-imidazole. The
phthalamide protecting group was removed with hydrazine monohydrate, resulting in the
amino-octyl-imidazole product. The alkylimidazole was then coupled with Nα-BOC-Nω-
nitroarginine by reaction with DCC, followed by deprotection of the BOC group with TFA,
affording the imidC8argNO2 ligand. The final step of the synthesis was metalation of the ligand
with [Re(CO)3(4,7-Me2phen)(THF)]BF4, yielding [ReC8argNO2]BF4.
Binding [ReC8argNO2]+ to iNOSoxy
Addition of L-arginine to iNOSoxy causes a blue shift in the heme Soret peak from 423 (six-
coordinate, resting-state Fe(III)) to 390 nm (high-spin, five-coordinate Fe(III)).19 The heme
Soret peak of the protein shifts from 423 to 390 nm, owing to partial displacement of the water
ligand from the active site of iNOSoxy, as occurs when arginine binds (Figure 1). Samples of
iNOSoxy with different concentrations of imidazole (5, 10, 30, and 50 µM) were titrated with
[ReC8argNO2]BF4 (up to 100 µM). Absorption peak shifts (427 to 390 nm) confirmed that
[ReC8argNO2]+ displaces imidazole from the active site. Double reciprocal plots are consistent
with competition between [ReC8argNO2]+ and imidazole for the iNOSoxy binding site (Figure
2). The Kd of 3.0 ± 0.1 µM obtained for iNOSoxy:[ReC8argNO2]+ is much smaller than those
for arginine (22 ± 5 µM) and imidazole (14 ± 3 µM) conjugates with the enzymes.
[ReC8argNO2]+:iNOSoxy Structural Model
The location of [ReC8argNO2]+ in the iNOSoxy active site was estimated by computer modeling
(DS Viewer Pro software package; PDB code 1NOD)5 (Figure 3). The arginine end of the wire
is parallel to the heme in an orientation similar to that in the arginine conjugate. Hydrogen
bonding interactions between the guanidinium group of the wire and Gly365, Trp366, and
Glu371 residues are retained in the model. The Re(I) complex was placed at the opening of the
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active-site channel, closely interacting with two tryptophan residues (Trp490 and Trp84
estimated to be 2.98 and 4.96 Å from the phenanthroline ligand). The opening of the active-
site channel is about 20 Å from the center of the heme.
[ReC8argNO2]+ Luminescence
The luminescence intensity of electronically excited [ReC8argNO2]BF4 decreases upon
addition of the wire in buffer to an iNOSoxy solution (Figure 4). The luminescence maximum
for ReC8argNO2 is at higher energy when the chromophore is bound in a protein environment
(550 nm) than when it is in buffer solution (570 nm). Scatchard analysis for wire:protein ratios
less than 4:1 yields a Kd of 2.0 ± 0.1 µM,20 a value in line with that extracted from competitive
binding experiments with imidazole (Kd = 3 ± 0.1 µM). At wire:protein ratios greater than 4:1,
a small amount of curvature is observed in the Scatchard plot, possibly indicating a second
[ReC8argNO2]+ binding on iNOSoxy (apparent Kd of 12 ± 1 µM).20
Luminescence decay traces (λex = 355 nm, λobs = 600 nm) were obtained for samples containing
[ReC8argNO2]BF4 in the absence of protein; Re(I)* decay was monoexponential with a
lifetime of 500 ns.20 Biexponential decay traces were obtained for samples with
[ReC8argNO2]BF4 in the presence of protein (Figure 5). The faster decay is attributable to *
[ReC8argNO2]+ bound to protein (τ = 92 ns), and the slower component corresponds to
uncomplexed *[ReC8argNO2]+ in buffer (τ = 500 ns). Luminescence decay traces were
obtained for various ratios of [ReC8argNO2]BF4-to-protein.20 All transient luminescence
traces of [ReC8argNO2]BF4 in the presence of protein exhibited biexponential decays with fast
(τ ~ 90 ns) and slow (τ ~ 500 ns) components.
[ReC8argNO2]+ Transient Absorbance
Single-wavelength transient absorption traces of solutions with varying [ReC8argNO2]
BF4:iNOSoxy ratios are shown in Figure 6. As the wire concentration increases, the *Re(I)
absorbance signal increases (~500 ns decay). A species with a much longer lifetime also is
generated; a difference spectrum of this transient features a bleach in the 390 – 435 nm region,
an isosbestic point at 438 nm, and an absorption increase maximizing near 445 nm (inset, Figure
6). The bleach at ~425 nm is attributable to reduction of the Fe(III); the increased absorption
at 445 nm is consistent with the spectrum of substrate-bound Fe(II)-iNOSoxy.21 Reduced,
substrate-bound iNOS is reported to have a Soret maximum near 413 nm that exhibits a
noticeable shoulder near 450 nm21–25 attributable to a high-spin ferrous heme. Indeed, the
difference spectrum shown in the inset to Figure 6 resembles that resulting from dithionite
titration of arginine-bound, BH4-depleted Fe(III)-eNOSoxy.21 Owing to overlapping signals
from the excited-state decay of free [ReC8argNO2]+ (τ = 500 ns), we were not able to measure
the kinetics of Fe(II) formation. We can nevertheless conclude that Fe(III) reduction is
complete in less than ~1 µs, orders of magnitude faster than reduction by the reductase domain
(kET = 0.9 – 1.5 s−1).26,27 It is important to note that the rate of the latter process may be
limited by large-scale protein conformational changes.
Steady-state absorption spectra of iNOSoxy (solid line, λmax = 423 nm) as well as
[ReC8argNO2]+-bound iNOSoxy recorded before (dotted line, λmax = 390 nm) and after (open
circles, λmax = 445 nm) excitation are shown in Figure 7 (inset is the difference spectrum).
After laser excitation, there is an intensity decrease in the 390 – 420 nm region and a slight
increase near 445 nm, attributable to the disappearance of five-coordinate Fe(III) and
appearance of Fe(II)-iNOSoxy. The Fe(II) species persists for hours before reoxidation occurs,
with return to the Fe(III) resting state.
We can only speculate on the mechanism of Fe(II) formation in [ReC8argNO2]+:iNOSoxy. A
first step could be reductive quenching of *[ReC8argNO2]+ by a nearby tryptophan residue
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(Trp490 or Trp84), generating Re(0) and a Trp radical cation. Direct, coupling-limited electron
tunneling from Re(0) to Fe(III) (~20 Å) could proceed on the microsecond timescale.28,29
More complex redox chemistry, possibly involving Trp+• oxidation of one of the three tyrosines
(Tyr483, Tyr484, Tyr485) near the heme (Figure 3), also may occur.9 Experiments with selected
mutants are planned to test these mechanistic proposals.
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Figure 1.
Absorption spectra of iNOSoxy in buffer (7.5 µM, solid line) and with 1:1
[ReC8argNO2]+:iNOSoxy (dotted line). The inset is the difference spectrum of the two
absorption traces, showing a type I perturbation.
Le Nguyen et al. Page 8
J Phys Chem B. Author manuscript; available in PMC 2008 December 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Double reciprocal plots from competitive binding studies between imidazole and
[ReC8argNO2]+: 1 / (Abs427 – Abs390) versus 1 / [ReC8argNO2]+. iNOSoxy (2µM) was titrated
with [ReC8argNO2]+ at a fixed concentration of imidazole for each sample: squares, 5 µM
imidazole; diamonds, 10 µM imidazole; triangles, 30 µM imidazole; circles, 50 µM imidazole.
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Figure 3.
Structural model of [ReC8argNO2]+:iNOSoxy: the arginine substrate is shown in green, the
heme in olive, and the[ReC8argNO2]+ wire in orange (based on the iNOS crystal structure,
PDB Code 1NOD, ref. 5). The model was designed to maximize the overlap between arginine
and the terminus of [ReC8argNO2]+.
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Figure 4.
Steady-state luminescence traces for [ReC8argNO2]BF4 in buffer (solid line) and 1:1
[ReC8argNO2]+:iNOSoxy (dotted line).
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Figure 5.
Luminescence decay traces for 4.8 µM [ReC8argNO2]+ (dashed line), 1:1
[ReC8argNO2]+:iNOSoxy (solid line). Biexponential fit (dots) and residuals (dotted line above)
for τ1 = 92 ns and τ2 = 500. The slow decay is free wire in solution and the fast decay is wire-
bound to protein (λex = 355, λobs = 600 nm).
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Figure 6.
Transient absorption kinetics of varying concentrations of [ReC8argNO2]+ in 9.6 µM
iNOSoxy (λex = 355, λobs = 443 nm, [ReC8argNO2]+:iNOSoxy: magenta, 0:1; blue, 1:1, green,
2:1; cyan, 3:1; red, 4:1). The negative spike is due to scattered laser light. Inset: Transient
difference spectra recorded at 1.5 (circles), 2.5 (triangles), and 3.5 µs (diamonds) after
excitation ([ReC8argNO2]+: iNOSoxy = 4:1).
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Figure 7.
Absorption spectra of iNOSoxy (solid line), [ReC8argNO2]+ bound iNOSoxy before (dashed
line) and after (open circles) excitation. The difference spectrum is shown in the inset (λmin =
423 nm; λmax = 445 nm).
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Scheme 1.
Synthesis of [ReC8argNO2]BF4.
Le Nguyen et al. Page 15
J Phys Chem B. Author manuscript; available in PMC 2008 December 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
